GRAL GRAIL Corp: Rasio Kapitalisasi Pasar marang Nilai Buku

GRAIL, Inc. (GRAL) has developed the innovative Galleri method for detecting fifty types of malignant neoplasms via blood analysis. This price chart illustrates the asset's dynamics, with a metric of 2.47. The business relies on unique patents and a massive array of medical data, creating barriers to entry for competitors. High-precision robots and AI process the data, although the final verdict remains with a specialized physician.

GRAIL, Inc. (GRAL) - Rasio Kapitalisasi Pasar marang Nilai Buku saka 29.06.2024 nganti 27.10.2026

GRAL (GRAIL Inc): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:

Bagan rega GRAIL, Inc.|GRAL - Bagan rega target

- data kapitalisasi pasar:

Kapitalisasi pasar GRAIL Corp|GRAL - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Buku saben Saham GRAIL|GRAL - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku grail.com|GRAL - Total Aset Bisnis

- data utang lan likuiditas:

Total Utang marang Modal GRAIL, Inc.|GRAL - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal GRAIL Corp|GRAL - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku GRAIL Corp

Pambiji fundamental:GRAL (GRAIL, Inc.)

The investor utilizes this indicator to stress-test positions by determining the gap between market expectations and the actual net asset value. The uniqueness of the Galleri test and the inelastic demand for early cancer detection support a high premium, which is reflected in the ratio of GRAIL, Inc. (GRAL) market capitalization to its book value as a marker of confidence in future technological breakthroughs.

Pesaing utama